Compare CWT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | WGS |
|---|---|---|
| Founded | 1926 | 2017 |
| Country | United States | United States |
| Employees | 1105 | 1300 |
| Industry | Water Supply | Retail: Computer Software & Peripheral Equipment |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1997 | N/A |
| Metric | CWT | WGS |
|---|---|---|
| Price | $43.94 | $66.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $54.50 | ★ $140.71 |
| AVG Volume (30 Days) | 377.0K | ★ 664.2K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $963,695,000.00 | N/A |
| Revenue This Year | $10.38 | $29.98 |
| Revenue Next Year | $5.80 | $26.04 |
| P/E Ratio | ★ $20.63 | $1,251.58 |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $41.29 | $55.17 |
| 52 Week High | $51.23 | $170.87 |
| Indicator | CWT | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 34.74 |
| Support Level | $42.33 | $61.55 |
| Resistance Level | $46.88 | $76.21 |
| Average True Range (ATR) | 1.06 | 4.60 |
| MACD | -0.11 | -0.51 |
| Stochastic Oscillator | 39.33 | 1.20 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.